Market Closed -
Nasdaq
04:00:00 2024-06-05 pm EDT
|
5-day change
|
1st Jan Change
|
4.85
USD
|
+2.54%
|
|
+7.54%
|
+13.85%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
482.4
|
161.4
|
42.41
|
263.1
|
292.6
|
-
|
-
|
Enterprise Value (EV)
1 |
482.4
|
161.4
|
42.41
|
263.1
|
292.6
|
292.6
|
292.6
|
P/E ratio
|
-4.04
x
|
-2.84
x
|
-0.59
x
|
-3.11
x
|
-2.97
x
|
-3.05
x
|
-2.85
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
25.5
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
25.5
x
|
EV / EBITDA
|
-8.49
x
|
-2.88
x
|
-0.62
x
|
-3.52
x
|
-3.12
x
|
-2.64
x
|
-
|
EV / FCF
|
-13.2
x
|
-
|
-
|
-
|
-2.66
x
|
-1.95
x
|
-1.62
x
|
FCF Yield
|
-7.57%
|
-
|
-
|
-
|
-37.6%
|
-51.3%
|
-61.9%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
23,373
|
23,665
|
40,394
|
61,761
|
61,856
|
-
|
-
|
Reference price
2 |
20.64
|
6.820
|
1.050
|
4.260
|
4.730
|
4.730
|
4.730
|
Announcement Date
|
3/25/21
|
3/15/22
|
3/22/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
11.48
|
EBITDA
1 |
-
|
-56.82
|
-55.97
|
-67.93
|
-74.81
|
-93.85
|
-110.9
|
-
|
EBIT
1 |
-
|
-57.04
|
-56.65
|
-68.68
|
-75.64
|
-104.1
|
-124.5
|
-144.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,255.45%
|
Earnings before Tax (EBT)
1 |
-
|
-56.42
|
-56.62
|
-67.06
|
-71.17
|
-100.7
|
-121.7
|
-141.2
|
Net income
1 |
-
|
-56.42
|
-56.62
|
-67.06
|
-71.17
|
-100.7
|
-121.7
|
-141.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,229.8%
|
EPS
2 |
-2.230
|
-5.110
|
-2.400
|
-1.780
|
-1.370
|
-1.590
|
-1.550
|
-1.659
|
Free Cash Flow
1 |
-
|
-36.54
|
-
|
-
|
-
|
-110
|
-150
|
-181
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,576.01%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/2/20
|
3/25/21
|
3/15/22
|
3/22/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.76
|
-16.84
|
-15.39
|
-16.91
|
-19.53
|
-18.37
|
-16.39
|
-18.07
|
-22.81
|
-24.34
|
-25.05
|
-26.66
|
-28.1
|
-30.98
|
-32.72
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-18.75
|
-16.88
|
-15.26
|
-16.37
|
-18.54
|
-17.4
|
-15.58
|
-16.64
|
-21.54
|
-23.35
|
-24.7
|
-26.32
|
-28.08
|
-30.73
|
-32.47
|
Net income
1 |
-18.75
|
-16.88
|
-15.26
|
-16.37
|
-18.54
|
-17.4
|
-15.58
|
-16.64
|
-21.54
|
-23.35
|
-24.25
|
-25.74
|
-27.3
|
-30.73
|
-32.47
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7900
|
-0.7100
|
-0.3800
|
-0.3800
|
-0.3100
|
-0.4000
|
-0.3500
|
-0.2900
|
-0.3500
|
-0.3800
|
-0.3900
|
-0.4014
|
-0.4186
|
-0.4600
|
-0.4300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/15/22
|
5/10/22
|
8/15/22
|
11/10/22
|
3/22/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/12/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-36.5
|
-
|
-
|
-
|
-110
|
-150
|
-181
|
ROE (net income / shareholders' equity)
|
-
|
-90.4%
|
-42.4%
|
-58.9%
|
-
|
-60.2%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-3.260
|
-2.040
|
-1.530
|
-
|
-1.360
|
-1.430
|
-
|
Capex
1 |
-
|
0.57
|
0.4
|
0.41
|
-
|
0.06
|
0.07
|
0.07
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.61%
|
Announcement Date
|
7/2/20
|
3/25/21
|
3/15/22
|
3/22/23
|
3/12/24
|
-
|
-
|
-
|
Last Close Price
4.73
USD Average target price
19.43
USD Spread / Average Target +310.75% Consensus |
1st Jan change
|
Capi.
|
---|
| +13.85% | 293M | | +55.70% | 55.7B | | +41.08% | 39.91B | | -5.39% | 39.57B | | -5.56% | 28.16B | | +16.46% | 26.3B | | -20.56% | 18.94B | | +33.03% | 12.17B | | +25.85% | 12.12B | | +2.72% | 12.12B |
Other Biotechnology & Medical Research
|